<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18409">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019810</url>
  </required_header>
  <id_info>
    <org_study_id>2013-003276-13</org_study_id>
    <nct_id>NCT02019810</nct_id>
  </id_info>
  <brief_title>Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury</brief_title>
  <acronym>DEBITC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France:National Agency for Drugs and Medical Products Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe traumatic brain injury with increased intracranial pressure can lead to decreased
      cerebral blood flow. Low cerebral blood flow is responsible for secondary lesions, leading
      to bad prognosis. It is not yet established whether increasing cardiac output in these
      patients can lead to an increase in cerebral blood flow, although there are some arguments
      in favor of this hypothesis. The aim of this study is to demonstrate that increasing cardiac
      output will improve cerebral blood flow in patients with severe traumatic injury and high
      cerebral pressure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean blood flow velocity</measure>
    <time_frame>After one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean blood flow velocity averaged on the two middle cerebral arteries (right and left) measured one after after the initiation of treatment. Each velocity is calculated as an average on the 10 last minutes form continuous transcranial doppler monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of brain oxygenation under treatment</measure>
    <time_frame>During one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the  brain tissue oxygenation curves (PbrO2) under treatment with and without dobutamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dobutamine doses</measure>
    <time_frame>After one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dobutamine doses required to reach the same cerebral perfusion pressure than noradrenaline alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistivity index on renal doppler</measure>
    <time_frame>After one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of resistivity index on renal doppler after one hour of treatment with and without dobutamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulsatility index on renal doppler</measure>
    <time_frame>After one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of pulsatility index (PI) on renal doppler before and after one hour of treatment with and without dobutamine prediction of cerebral blood flow increase (patients with high initial renal PI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output modifications</measure>
    <time_frame>During one hour of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of cardiac blood flow modifications under treatment for one hour  with and without dobutamine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Traumatic Brain Injury With High Cerebral Pressure</condition>
  <arm_group>
    <arm_group_label>Noradrenaline alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment for one hour with noradrenaline alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Noradrenaline + dobutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with noradrenaline and dobutamine for one hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <arm_group_label>Noradrenaline alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dobutamine and norepinephrine</intervention_name>
    <arm_group_label>Noradrenaline + dobutamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic brain injury (TBI) with pattern of oligemia (diastolic velocity &lt;
             20cm/second and/or mean velocity &lt; 30cm/second measured with transcranial doppler or
             oxygen tissue pressure &lt; 15mmHg)

          -  Closed traumatic brain injury

          -  Isolated TBI or polytraumatism

          -  Age between 18 and 65 years old

          -  Affiliated to a social security system

        Exclusion Criteria:

          -  Instable episodes of high cerebral pressure

          -  Craniectomy

          -  High cerebral pressure without TBI

          -  No autoregulation

          -  Current hemorrhagic shock

          -  Chronic cardiac failure

          -  Chronic renal failure

          -  Hyperemia measured with transcranial doppler

          -  Short life expectancy

          -  Refused consent from the family

          -  Protected patients by the law

          -  Hypersensibility to one of the treatment or sulfites
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilles Francony, MD</last_name>
    <phone>0033476766688</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gilles Francony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Bouzat, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Payen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Lavagne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Picard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Falcon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine Herault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Declety, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Vinclair, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Cécile Fevre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Canet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dobutamine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
